Quality of life and symptom burden in hematological cancer patients receiving hematopoietic stem cell transplantation: an observational study at Regional Cancer Centre, India
ConclusionSymptom burden is maximum during the first month of BMT, which improves later and QOL becomes improved with time. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - April 8, 2024 Category: Cancer & Oncology Source Type: research
COVID-19 surveillance in a bone marrow transplantation unit: experience from a Brazilian tertiary-care teaching hospital
CONCLUSION: We postulate that diagnosing these patients and isolating them outside the transplantation unit may have prevented secondary symptomatic cases.PMID:38581472 | DOI:10.1007/s00520-024-08479-2 (Source: Cancer Control)
Source: Cancer Control - April 6, 2024 Category: Cancer & Oncology Authors: Bruno A Randi Tha ís Guimarães Fernanda de S Spadao Hermes R Higashino Carolina Dos S Lazari Erick M Xavier Vanderson Rocha Silvia F Costa Source Type: research
COVID-19 surveillance in a bone marrow transplantation unit: experience from a Brazilian tertiary-care teaching hospital
CONCLUSION: We postulate that diagnosing these patients and isolating them outside the transplantation unit may have prevented secondary symptomatic cases.PMID:38581472 | DOI:10.1007/s00520-024-08479-2 (Source: Cancer Control)
Source: Cancer Control - April 6, 2024 Category: Cancer & Oncology Authors: Bruno A Randi Tha ís Guimarães Fernanda de S Spadao Hermes R Higashino Carolina Dos S Lazari Erick M Xavier Vanderson Rocha Silvia F Costa Source Type: research
COVID-19 surveillance in a bone marrow transplantation unit: experience from a Brazilian tertiary-care teaching hospital
ConclusionWe postulate that diagnosing these patients and isolating them outside the transplantation unit may have prevented secondary symptomatic cases. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - April 6, 2024 Category: Cancer & Oncology Source Type: research
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Bone Marrow Transplant. 2024 Apr 5. doi: 10.1038/s41409-024-02266-7. Online ahead of print.ABSTRACTAllogeneic hematopoietic stem cell transplantation (allo-HSCT) offers rapid hematopoietic and immune reconstitution for aplastic anemia (AA). As a non-malignant disorder, attenuation of GVHD remains a clinical priority in AA patients. Our study sought to investigate the safety and efficacy of the prophylactic use of ruxolitinib in allogeneic HSCT. A total of 35 AA patients were retrospectively consecutively treated with allo-HSCT whereby ruxolitinib was added to the standard GVHD prophylaxis regimen (rux group). The addition ...
Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Xiaoyu Zhang Xiaoli Zhao Shulian Chen Mengze Hao Lining Zhang Ming Gong Yuanyuan Shi Jialin Wei Ping Zhang Sizhou Feng Yi He Erlie Jiang Mingzhe Han Source Type: research
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Bone Marrow Transplantation, Published online: 05 April 2024; doi:10.1038/s41409-024-02266-7Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - April 5, 2024 Category: Hematology Authors: Xiaoyu Zhang Xiaoli Zhao Shulian Chen Mengze Hao Lining Zhang Ming Gong Yuanyuan Shi Jialin Wei Ping Zhang Sizhou Feng Yi He Erlie Jiang Mingzhe Han Source Type: research
Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience
Bone Marrow Transplantation, Published online: 02 April 2024; doi:10.1038/s41409-024-02276-5Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - April 2, 2024 Category: Hematology Authors: Rui Ma Dan-Ping Zhu Xiao-Hui Zhang Lan-Ping Xu Yu Wang Xiao-Dong Mo Meng Lv Yuan-Yuan Zhang Yi-Fei Cheng Chen-Hua Yan Yu-Hong Chen Yao Chen Jing-Zhi Wang Feng-Rong Wang Ting-Ting Han Jun Kong Zhi-Dong Wang Wei Han Huan Chen Ying-Jun Chang Yun He Zheng-Li Source Type: research
Utah flouts FDA with law greenlighting placental stem cell therapies
The state of Utah is challenging the authority of the U.S. Food and Drug Administration (FDA) with a new, unusually bold law that allows patients to receive unapproved placental stem cell “therapies.” Observers predict that the law, which takes effect on 1 May, could significantly undermine FDA’s authority to regulate drugs and other treatments.
The
new statute
, passed almost unanimously by both houses of the Utah legislature in February and signed by Governor Spencer Cox (R) last month, declares that Utah health care providers “may perform a [placental] stem cell therapy that is not approved by [F...
Source: Science of Aging Knowledge Environment - April 1, 2024 Category: Geriatrics Source Type: research
IL-6–mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation
Endothelial function and integrity are compromised after allogeneic bone marrow transplantation (BMT), but how this affects immune responses broadly remains unknown. Using a preclinical model of CMV reactivation after BMT, we found compromised antiviral humoral responses induced by IL-6 signaling. IL-6 signaling in T cells maintained Th1 cells, resulting in sustained IFN-γ secretion, which promoted endothelial cell (EC) injury, loss of the neonatal Fc receptor (FcRn) responsible for IgG recycling, and rapid IgG loss. T cell–specific deletion of IL-6R led to persistence of recipient-derived, CMV-specific IgG and inhibite...
Source: Journal of Clinical Investigation - April 1, 2024 Category: Biomedical Science Authors: Ping Zhang, Peter Fleming, Christopher E. Andoniou, Olivia G. Waltner, Shruti S. Bhise, Jose Paulo Martins, Benjamin A. McEnroe, Valentina Voigt, Sheridan Daly, Rachel D. Kuns, Adaeze P. Ekwe, Andrea S. Henden, Alda Saldan, Stuart Olver, Antiopi Varelias, Source Type: research
5. Human Papillomavirus Vaccination Uptake in Adolescent Survivors of Bone Marrow Transplant
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States and can lead to cervical, oropharyngeal, and anogenital dysplasia and malignancy. Vaccination against HPV is recommended for all adolescents but is particularly important in patients with a history of bone marrow transplant (BMT) as they can have higher rates of persistent HPV-related disease or secondary cancers. Because of lost or reduced immunity after BMT, patients who previously received the vaccine must be re-vaccinated after transplant. (Source: Journal of Pediatric and Adolescent Gynecology)
Source: Journal of Pediatric and Adolescent Gynecology - April 1, 2024 Category: OBGYN Authors: Aimee Morrison, Kasiani Myers, Tara Streich-Tilles Source Type: research
Building a Transplant Center: From the Karolinska to Kathmandu
In the Icelandic language, the word von means hope, an uplifted spirit, persistence and enduring resilience. From the founding of bone marrow transplantation (BMT) by Don Thomas and other pioneers, this Nordic term has come to symbolize the journey of both transplant recipients and their physicians. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2024 Category: Hematology Authors: Olle Ringden, Damiano Rondelli Tags: Reflections Source Type: research
Donor Chimerism Duration Correlates with Heart Allograft Tolerance in Combined Heart and Bone Marrow Transplantation in Nonhuman Primates
In this study, we asked whether chimerism peak and/or duration correlated with the long-term heart allograft tolerance we have induced for the first time in NHPs using a modified protocol. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J.T. Nawalaniec, S.M. Landino, J.M. O, A. Dehnadi, C.L. Miller, D. Muldoon, I.M. Hanekamp, J.C. Madsen, J.S. Allan Source Type: research
Heart and Lung Transplant in a Patient with Relapsed AL Amyloidosis
Introduction: AL amyloidosis is a systemic disease of abnormal light chain production and pathologic amyloid fibrils that infiltrate tissue and lead to organ dysfunction. Solid organ transplantation historically has played a small role in management due to concerns of multi-organ involvement and risk of relapse. Standard of care previously included cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For relapsed disease, treatment options often included immunomodulatory drugs that are associated with an increased risk of transplant rejection or autologous bone marrow transplant. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Urey, E. Adler, V. Pretorius, M. Kearns, E. Golts, A. Kao, G. Yung, A. Kafi, C. Lin, C. Costello, K. Afshar Source Type: research
IL-6 Blockade Promotes Tolerance of Heart but Not Lung Allografts in Non-Human Primate Simultaneous Organ and Bone Marrow Transplantation Protocols
Purpose: We previously achieved tolerance of heart allografts in non-human primates (NHPs) using IL-6 signaling blockade in a mixed-chimerism protocol where donor bone marrow transplantation (BMT) occurs simultaneously with solid organ transplantation. Here, we report the differential effect of adding aIL-6R mAb therapy to a simultaneous mixed-chimerism protocol for heart and lung transplantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J.T. Nawalaniec, J. O, A. Dehnadi, N. Hays, J. Muoio, C. Winter, I. Hanekamp, J. Madsen, J.S. Allan Source Type: research
Efficacy and Safety if JAK2 Inhibitor Plus Extracorporeal Photopheresis in Chronic Lung Allograft Dysfunction: A Single Centre Experience
Purpose: Post lung transplantation survival is limited by the development of chronic lung allograft dysfunction(CLAD),for which only few effective therapies exists and no standardized management. There are studies showing proven benefits of JAK2 inhibitor plus ECP in post bone marrow transplantation GVHD patients.We analysed JAK2 inhibitor plus ECP therapy in clinically diagnosed CLAD. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , V. Rahulan, M. Lalani, O. Tisekar, S. Priyaranjan, P. Dutta, A. Mohandas, M. B N, M. M, M. Sameer, S. Attawar Source Type: research
